Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
A key Japanese health ministry panel on August 3 recommended approval of Takeda Pharmaceutical’s orexin receptor agonist oveporexton, putting the country’s first narcolepsy type 1 (NT1) treatment on track for clearance. The Pharmaceutical Affairs Council’s First Committee on Drugs endorsed…
To read the full story
Related Article
- Japan Grants Sakigake Tag to NS-035, MSA-01
August 26, 2026
- Japan Approves Takeda’s Orzeyful, Insmed’s Brinsupri and More Drugs
August 25, 2026
- Japan Grants Orphan Tags to Rogocekib, Gildeuretinol, and More
August 25, 2026
- Japan Extends Re-Examination Period for Uplizna
August 25, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Japan Review Underway for Rhythm’s Acquired Hypothalamic Obesity Drug
May 11, 2026
- Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
March 5, 2026
- Allergan Seeks Label Expansion for Botox Vista in Japan
September 22, 2025
REGULATORY
- MOF Panel Pushes for Full Drug Price Revision in FY2027: Budget Proposal
November 20, 2026
- Mumps Shots Gain Strong Backing as Japan Weighs FY2027 NIP Priorities
November 20, 2026
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- Pharma Prods LDP to Rethink CEA Expansion, Project Team to Compile Proposal
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026





